Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H17BrN4.ClH |
| Molecular Weight | 333.655 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)C1=CC=C(Br)C(N=C2NCCN2)=C1C
InChI
InChIKey=QTAUWYULRRTZNV-UHFFFAOYSA-N
InChI=1S/C12H17BrN4.ClH/c1-8-10(17(2)3)5-4-9(13)11(8)16-12-14-6-7-15-12;/h4-5H,6-7H2,1-3H3,(H2,14,15,16);1H
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
850715-60-5
Created by
admin on Mon Mar 31 20:38:16 GMT 2025 , Edited by admin on Mon Mar 31 20:38:16 GMT 2025
|
PRIMARY | |||
|
140120264
Created by
admin on Mon Mar 31 20:38:16 GMT 2025 , Edited by admin on Mon Mar 31 20:38:16 GMT 2025
|
PRIMARY | |||
|
P2BY9PUC48
Created by
admin on Mon Mar 31 20:38:16 GMT 2025 , Edited by admin on Mon Mar 31 20:38:16 GMT 2025
|
PRIMARY | |||
|
ESR-1150-CL
Created by
admin on Mon Mar 31 20:38:16 GMT 2025 , Edited by admin on Mon Mar 31 20:38:16 GMT 2025
|
PRIMARY | Official Title: Administration of ESR 1150 CL in Ascending Doses of 0.5, 1, 2, 4 and 8 mg in an Open, Group Comparison and Placebo-controlled Design (Placebo Randomised Double Blind in the Dose Groups) for the Assessment of Safety, Tolerability (Maximum Tolerated Dose, MTD), Pharmacokinetics and Pharmacodynamics in 5 Groups of 8 Female and 5 Male Healthy Subjects, and 4 mg Additionally in Fed State, in a Cross Over Design. Safety, Tolerability and Pharmacokinetics of MTD/4, MTD/2 and MTD in 6 Healthy Male Subjects, Identified as CYP2D6 and/or "Spartein" Poor Metabolizers, in a 3-fold Cross Over, Open Study. |
SUBSTANCE RECORD
